FGFR1 and cholangiocarcinoma: Erdafitinib (JNJ-42756493) is an oral pan-FGFR inhibitor (FGFR1–4) that showed a partial response in 3 of 11 CCA patients with an FGFR2-fusion or mutation [65], but there is not yet available information of mechanisms of resistance.